FAT CATS

[lady*b]

afterhours: IOMI: 1.70 Iomai to Announce Positive Results from Phase 2 Field Trial of Its Travelers Diarrhea Vaccine and Host Conference Call and Webcast Tomorrow
Tuesday July 31, 6:05 pm ET


GAITHERSBURG, Md., July 31 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI - News) today announced that it will announce positive results from the Phase 2 field trial of the company's patch-based travelers' diarrhea vaccine before the markets open tomorrow. A conference call and live webcast will be held at 8:30 a.m. Eastern Time tomorrow to discuss the results.

Conference Call Details

To access the live conference call tomorrow at 8:30 a.m. Eastern Time via phone, please dial 866-510-0705 from the United States and Canada or 617-597- 5363 internationally. The conference ID is 26738905. Please dial in approximately ten minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through Aug. 8 and may be accessed by dialing 888-286-8010 from the United States and Canada or 617-801-6888 internationally. The replay passcode is 85144095.

To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the Company's website at www.iomai.com. Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary. The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at www.earnings.com, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (www.streetevents.com), a password-protected event management site.

ABOUT IOMAI CORPORATION

Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent travelers' diarrhea. For more information on Iomai, please visit www.iomai.com.




--------------------------------------------------------------------------------
Source: Iomai Corporation


http://biz.yahoo.com/prnews/070731/aqtu220.html?.v=4